

New horizons in adjuvants for vaccine development

Current Opinion in Immunology

65, 97-101

DOI: [10.1016/j.coi.2020.08.008](https://doi.org/10.1016/j.coi.2020.08.008)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Enhancement of Tumour-Specific Immune Responses In Vivo by â€˜MHC Loading-Enhancerâ€™™ (MLE). PLoS ONE, 2009, 4, e6811.	1.1	13
2	Detailed analysis for inducing specific CD8 T cells via a CpG-DNA adjuvant. Expert Review of Vaccines, 2009, 8, 699-703.	2.0	0
3	Protective immunity to influenza: lessons from the virus for successful vaccine design. Expert Review of Vaccines, 2009, 8, 689-693.	2.0	5
4	Novel Vaccines to Human Rabies. PLoS Neglected Tropical Diseases, 2009, 3, e515.	1.3	63
5	Plants as bioreactors for the production of vaccine antigens. Biotechnology Advances, 2009, 27, 449-467.	6.0	163
6	Adjuvants for malaria vaccines. Parasite Immunology, 2009, 31, 520-528.	0.7	61
7	Prospects for an influenza vaccine that induces crossâ€™protective cytotoxic T lymphocytes. Immunology and Cell Biology, 2009, 87, 300-308.	1.0	91
8	Vaccines: the Fourth Century. Vaccine Journal, 2009, 16, 1709-1719.	3.2	205
9	Adjuvants and autoimmunity. Lupus, 2009, 18, 1217-1225.	0.8	228
10	ISCOMs and ISCOMATRIXâ„¢. Vaccine, 2009, 27, 4388-4401.	1.7	205
11	Enhancement of in vivo and in vitro immune functions by a conformationally biased, response-selective agonist of human C5a: Implications for a novel adjuvant in vaccine design. Vaccine, 2009, 28, 463-469.	1.7	24
12	Chitosan-based systems for the delivery of vaccine antigens. Expert Review of Vaccines, 2009, 8, 937-953.	2.0	158
13	Immunological mechanisms underlying protection mediated by RTS,S: a review of the available data. Malaria Journal, 2009, 8, 312.	0.8	107
14	Novel adjuvants for B cell immune responses. Current Opinion in HIV and AIDS, 2009, 4, 441-446.	1.5	18
15	Pediatric Vaccines on the Horizon. American Journal of the Medical Sciences, 2010, 340, 226-231.	0.4	2
16	Synthetic and Natural TLR4 Agonists as Safe and Effective Vaccine Adjuvants. Sub-Cellular Biochemistry, 2010, 53, 303-321.	1.0	56
17	Archaeal lipid mucosal vaccine adjuvant and delivery system. Expert Review of Vaccines, 2010, 9, 431-440.	2.0	21
18	Future Vaccination Strategies against Tuberculosis: Thinking outside the Box. Immunity, 2010, 33, 567-577.	6.6	154

#	ARTICLE	IF	CITATIONS
19	Comparison of BCG, MPL and cationic liposome adjuvant systems in leishmanial antigen vaccine formulations against murine visceral leishmaniasis. <i>BMC Microbiology</i> , 2010, 10, 181.	1.3	47
21	CD14-independent responses induced by a synthetic lipid A mimetic. <i>European Journal of Immunology</i> , 2010, 40, 797-802.	1.6	16
22	Chemical Synthesis and Proinflammatory Responses of Monophosphoryl Lipid A Adjuvant Candidates. <i>European Journal of Organic Chemistry</i> , 2010, 2010, 80-91.	1.2	23
23	Intravital microscopy imaging of macrophage localization to immunogenic particles and co-localized tissue oxygen saturation. <i>Acta Biomaterialia</i> , 2010, 6, 3491-3498.	4.1	23
24	Adjuvants in tuberculosis vaccine development. <i>FEMS Immunology and Medical Microbiology</i> , 2010, 58, 75-84.	2.7	17
25	Enhancement of humoral and cellular immunity with an anti-glucocorticoid-induced tumour necrosis factor receptor monoclonal antibody. <i>Immunology</i> , 2010, 130, 231-242.	2.0	23
26	Immunomodulators as adjuvants for vaccines and antimicrobial therapy. <i>Annals of the New York Academy of Sciences</i> , 2010, 1213, 46-61.	1.8	89
27	Combination of Pneumococcal Surface Protein A (PspA) with Whole Cell Pertussis Vaccine Increases Protection Against Pneumococcal Challenge in Mice. <i>PLoS ONE</i> , 2010, 5, e10863.	1.1	40
28	A Novel Laser Vaccine Adjuvant Increases the Motility of Antigen Presenting Cells. <i>PLoS ONE</i> , 2010, 5, e13776.	1.1	65
29	The Protein Moiety of <i>Brucella abortus</i> Outer Membrane Protein 16 Is a New Bacterial Pathogen-Associated Molecular Pattern That Activates Dendritic Cells In Vivo, Induces a Th1 Immune Response, and Is a Promising Self-Adjuvanting Vaccine against Systemic and Oral Acquired Brucellosis. <i>Journal of Immunology</i> , 2010, 184, 5200-5212.	0.4	63
30	The M Cell-Targeting Ligand Promotes Antigen Delivery and Induces Antigen-Specific Immune Responses in Mucosal Vaccination. <i>Journal of Immunology</i> , 2010, 185, 5787-5795.	0.4	107
31	Role of adjuvants in modeling the immune response. <i>Current Opinion in HIV and AIDS</i> , 2010, 5, 409-413.	1.5	48
32	Adjuvant Activity on Murine and Human Macrophages. <i>Methods in Molecular Biology</i> , 2010, 626, 117-130.	0.4	1
33	Blood-stage malaria vaccines – recent progress and future challenges. <i>Annals of Tropical Medicine and Parasitology</i> , 2010, 104, 189-211.	1.6	75
35	Production of H5N1 (NIBRG-14) inactivated whole virus and split virion influenza vaccines and analysis of immunogenicity in mice using different adjuvant formulations. <i>Vaccine</i> , 2010, 28, 2505-2509.	1.7	24
36	Identification of <i>T. gondii</i> epitopes, adjuvants, and host genetic factors that influence protection of mice and humans. <i>Vaccine</i> , 2010, 28, 3977-3989.	1.7	66
37	Influenza antigen-sparing by immune stimulation with Gram-positive enhancer matrix (GEM) particles. <i>Vaccine</i> , 2010, 28, 7963-7969.	1.7	28
38	A review of adjuvants for <i>Leishmania</i> vaccine candidates. <i>Journal of Biomedical Research</i> , 2010, 24, 16-25.	0.7	43

#	ARTICLE	IF	CITATIONS
39	Directing dendritic cell immunotherapy towards successful cancer treatment. <i>Immunotherapy</i> , 2010, 2, 37-56.	1.0	113
40	Is the choice of vaccine adjuvant critical for long-term memory development?. <i>Expert Review of Vaccines</i> , 2010, 9, 1357-1361.	2.0	6
41	Liposomes containing glucosyl ceramide specifically bind T4 bacteriophage: a self-assembling nanocarrier formulation. <i>Journal of Liposome Research</i> , 2011, 21, 279-285.	1.5	0
42	Tuberculosis vaccines in clinical trials. <i>Expert Review of Vaccines</i> , 2011, 10, 645-658.	2.0	90
43	Design of a shear-thinning recoverable peptide hydrogel from native sequences and application for influenza H1N1 vaccine adjuvant. <i>Soft Matter</i> , 2011, 7, 8905.	1.2	53
44	The long-term potential of biodegradable poly(lactide-co-glycolide) microparticles as the next-generation vaccine adjuvant. <i>Expert Review of Vaccines</i> , 2011, 10, 1731-1742.	2.0	101
45	Inactivated Influenza Vaccines. <i>Drugs and Aging</i> , 2011, 28, 93-106.	1.3	43
46	Confronting the barriers to develop novel vaccines against brucellosis. <i>Expert Review of Vaccines</i> , 2011, 10, 1291-1305.	2.0	48
47	Collagen Type II and a Thermo-Responsive Polymer of N-Isopropylacrylamide Induce Arthritis Independent of Toll-Like Receptors. <i>American Journal of Pathology</i> , 2011, 179, 2490-2500.	1.9	11
48	Induction of antigen-specific immunity by pH-sensitive carbonate apatite as a potent vaccine carrier. <i>Biochemical and Biophysical Research Communications</i> , 2011, 415, 597-601.	1.0	7
49	Chitosan-Based Particulate Systems for Non-Invasive Vaccine Delivery. <i>Advances in Polymer Science</i> , 2011, , 111-137.	0.4	11
50	Naloxone and alum synergistically augment adjuvant activities of each other in a mouse vaccine model of <i>Salmonella typhimurium</i> infection. <i>Immunobiology</i> , 2011, 216, 744-751.	0.8	26
51	Application of the immunological disease continuum to study autoimmune and other inflammatory events after vaccination. <i>Vaccine</i> , 2011, 29, 913-919.	1.7	17
52	Highly effective generic adjuvant systems for orphan or poverty-related vaccines. <i>Vaccine</i> , 2011, 29, 873-877.	1.7	35
53	Carnauba wax nanoparticles enhance strong systemic and mucosal cellular and humoral immune responses to HIV-gp140 antigen. <i>Vaccine</i> , 2011, 29, 1258-1269.	1.7	37
54	Non-toxic derivatives of LT as potent adjuvants. <i>Vaccine</i> , 2011, 29, 1538-1544.	1.7	75
55	A novel non-toxic combined CTA1-DD and ISCOMS adjuvant vector for effective mucosal immunization against influenza virus. <i>Vaccine</i> , 2011, 29, 3951-3961.	1.7	49
56	Tumor-specific peptide-based vaccines containing the conformationally biased, response-selective C5a agonists EP54 and EP67 protect against aggressive large B cell lymphoma in a syngeneic murine model. <i>Vaccine</i> , 2011, 29, 5904-5910.	1.7	12

#	ARTICLE	IF	CITATIONS
57	Flagellin produced in plants is a potent adjuvant for oral immunization. <i>Vaccine</i> , 2011, 29, 6695-6703.	1.7	18
58	Adjuvant Properties of Cytosine-Phosphate-Guanosine Oligodeoxynucleotide in Combination with Various Polycations in an Ovalbumin-Vaccine Model. <i>Nucleic Acid Therapeutics</i> , 2011, 21, 231-240.	2.0	12
59	An Oral Vaccine Based on U-Omp19 Induces Protection against <i>B. abortus</i> Mucosal Challenge by Inducing an Adaptive IL-17 Immune Response in Mice. <i>PLoS ONE</i> , 2011, 6, e16203.	1.1	94
60	Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responses. <i>Nature Materials</i> , 2011, 10, 243-251.	13.3	498
62	Delivery of a cocktail DNA vaccine encoding cysteine proteinases type I, II and III with solid lipid nanoparticles potentiate protective immunity against <i>Leishmania major</i> infection. <i>Journal of Controlled Release</i> , 2011, 153, 154-162.	4.8	63
63	Harnessing immune responses against <i>Plasmodium</i> for rational vaccine design. <i>Trends in Parasitology</i> , 2011, 27, 274-283.	1.5	32
64	Particulate vaccines: on the quest for optimal delivery and immune response. <i>Drug Discovery Today</i> , 2011, 16, 569-582.	3.2	265
65	Current adjuvants and new perspectives in vaccine formulation. <i>Expert Review of Vaccines</i> , 2011, 10, 1053-1061.	2.0	106
66	Conjugation of Lipid and CpG-Containing Oligonucleotide Yields an Efficient Method for Liposome Incorporation. <i>Bioconjugate Chemistry</i> , 2011, 22, 1279-1286.	1.8	12
67	Construction of an <i>Escherichia coli</i> mutant producing monophosphoryl lipid A. <i>Biotechnology Letters</i> , 2011, 33, 1013-1019.	1.1	13
68	In vivo efficacy of a chitosan/IL-12 adjuvant system for protein-based vaccines. <i>Biomaterials</i> , 2011, 32, 926-932.	5.7	51
69	Systems biology applied to vaccine and immunotherapy development. <i>BMC Systems Biology</i> , 2011, 5, 146.	3.0	26
70	Health effects of GnRH immunocontraception of wild white-tailed deer in New Jersey. <i>Wildlife Society Bulletin</i> , 2011, 35, 149-160.	1.6	24
71	Alum-type Adjuvant Effect of Non-haemolytic Saponins Purified from <i>Ilex</i> and <i>Passiflora</i> spp.. <i>Phytotherapy Research</i> , 2011, 25, 1783-1788.	2.8	9
72	M cells expressing the complement C5a receptor are efficient targets for mucosal vaccine delivery. <i>European Journal of Immunology</i> , 2011, 41, 3219-3229.	1.6	63
73	Humoral responses and immune protection in mice immunized with irradiated <i>T. gondii</i> tachyzoites and challenged with three genetically distinct strains of <i>T. gondii</i> . <i>Immunology Letters</i> , 2011, 138, 187-196.	1.1	30
74	Laser vaccine adjuvant for cutaneous immunization. <i>Expert Review of Vaccines</i> , 2011, 10, 1397-1403.	2.0	38
75	Role of AS04 in human papillomavirus vaccine: mode of action and clinical profile. <i>Expert Opinion on Biological Therapy</i> , 2011, 11, 667-677.	1.4	56

#	ARTICLE	IF	CITATIONS
76	Adjuvant properties of a biocompatible thermo-responsive polymer of <i>N</i> -isopropylacrylamide in autoimmunity and arthritis. <i>Journal of the Royal Society Interface</i> , 2011, 8, 1748-1759.	1.5	28
77	<i>Salmonella</i> Synthesizing 1-Monophosphorylated Lipopolysaccharide Exhibits Low Endotoxic Activity while Retaining Its Immunogenicity. <i>Journal of Immunology</i> , 2011, 187, 412-423.	0.4	66
78	The Requirement for Potent Adjuvants To Enhance the Immunogenicity and Protective Efficacy of Protein Vaccines Can Be Overcome by Prior Immunization with a Recombinant Adenovirus. <i>Journal of Immunology</i> , 2011, 187, 2602-2616.	0.4	55
79	C-Terminal Domain Deletion Enhances the Protective Activity of cpa/cpb Loaded Solid Lipid Nanoparticles against <i>Leishmania major</i> in BALB/c Mice. <i>PLoS Neglected Tropical Diseases</i> , 2011, 5, e1236.	1.3	20
80	CD83 increases MHC II and CD86 on dendritic cells by opposing IL-10-driven MARCH1-mediated ubiquitination and degradation. <i>Journal of Experimental Medicine</i> , 2011, 208, 149-165.	4.2	183
81	A history of hookworm vaccine development. <i>Hum Vaccin</i> , 2011, 7, 1234-1244.	2.4	39
82	Phase I Safety and Immunogenicity Trial of Plasmodium vivax CS Derived Long Synthetic Peptides Adjuvanted with Montanide ISA 720 or Montanide ISA 51. <i>American Journal of Tropical Medicine and Hygiene</i> , 2011, 84, 12-20.	0.6	65
83	Adjuvant Effect of Microencapsulated NOD Ligands Studied in a Human Phagocytic Cell Line. <i>Journal of Applied Biomaterials and Functional Materials</i> , 2012, 10, 229-236.	0.7	3
84	Glucopyranosyl Lipid Adjuvant (GLA), a Synthetic TLR4 Agonist, Promotes Potent Systemic and Mucosal Responses to Intranasal Immunization with HIVgp140. <i>PLoS ONE</i> , 2012, 7, e41144.	1.1	96
85	The pH-Sensitive Fusogenic 3-Methyl-Glutarylated Hyperbranched Poly(Glycidol)-Conjugated Liposome Induces Antigen-Specific Cellular and Humoral Immunity. <i>Vaccine Journal</i> , 2012, 19, 1492-1498.	3.2	18
86	Suppression of Vaccine Immunity by Inflammatory Monocytes. <i>Journal of Immunology</i> , 2012, 189, 5612-5621.	0.4	36
87	Prime-boost regimens with adjuvanted synthetic long peptides elicit T cells and antibodies to conserved regions of HIV-1 in macaques. <i>Aids</i> , 2012, 26, 275-284.	1.0	35
88	Nanovaccines : nanocarriers for antigen delivery. <i>Biologie Aujourd'hui</i> , 2012, 206, 249-261.	0.1	25
89	Polyclonal Antibody Production. , 2012, , 259-274.		19
90	Optimizing efficacy of mucosal vaccines. <i>Expert Review of Vaccines</i> , 2012, 11, 1139-1155.	2.0	44
91	Molecular Interactions of a Polyaromatic Surfactant C5Pe in Aqueous Solutions Studied by a Surface Forces Apparatus. <i>Journal of Physical Chemistry B</i> , 2012, 116, 11187-11196.	1.2	38
92	The cationic lipid, diC14 amidine, extends the adjuvant properties of aluminum salts through a TLR-4- and caspase-1-independent mechanism. <i>Vaccine</i> , 2012, 30, 414-424.	1.7	21
93	A TLR4 agonist synergizes with dendritic cell-directed lentiviral vectors for inducing antigen-specific immune responses. <i>Vaccine</i> , 2012, 30, 2570-2581.	1.7	13

#	ARTICLE	IF	CITATIONS
94	A novel adjuvant, mixture of alum and the beta-adrenergic receptor antagonist propranolol, elicits both humoral and cellular immune responses for heat-killed <i>Salmonella typhimurium</i> vaccine. <i>Vaccine</i> , 2012, 30, 2640-2646.	1.7	23
95	Adjuvant solution for pandemic influenza vaccine production. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 17585-17590.	3.3	70
96	AF03, An Alternative Squalene Emulsion-Based Vaccine Adjuvant Prepared by a Phase Inversion Temperature Method. <i>Journal of Pharmaceutical Sciences</i> , 2012, 101, 4490-4500.	1.6	64
97	Recent developments in buccal and sublingual delivery systems. <i>Expert Opinion on Drug Delivery</i> , 2012, 9, 615-628.	2.4	57
98	Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome. <i>Expert Review of Vaccines</i> , 2012, 11, 1405-1413.	2.0	126
99	Mucosal Vaccine Design and Delivery. <i>Annual Review of Biomedical Engineering</i> , 2012, 14, 17-46.	5.7	182
100	<i>Salmonella enterica</i> as a vaccine carrier. <i>Future Microbiology</i> , 2012, 7, 111-127.	1.0	59
101	ISCOMATRIX vaccines mediate CD8 ⁺ T cell cross-priming by a MyD88-dependent signaling pathway. <i>Immunology and Cell Biology</i> , 2012, 90, 540-552.	1.0	92
102	Polymeric Multilayer Capsule-Mediated Vaccination Induces Protective Immunity Against Cancer and Viral Infection. <i>ACS Nano</i> , 2012, 6, 2136-2149.	7.3	116
103	Multiparameter Telemetry as a Sensitive Screening Method to Detect Vaccine Reactogenicity in Mice. <i>PLoS ONE</i> , 2012, 7, e29726.	1.1	5
104	Vault Nanocapsules as Adjuvants Favor Cell-Mediated over Antibody-Mediated Immune Responses following Immunization of Mice. <i>PLoS ONE</i> , 2012, 7, e38553.	1.1	35
105	Molecular and Cellular Response Profiles Induced by the TLR4 Agonist-Based Adjuvant Glucopyranosyl Lipid A. <i>PLoS ONE</i> , 2012, 7, e51618.	1.1	51
106	Robust Immunity and Heterologous Protection against Influenza in Mice Elicited by a Novel Recombinant NP-M2e Fusion Protein Expressed in <i>E. coli</i> . <i>PLoS ONE</i> , 2012, 7, e52488.	1.1	17
107	Human prophylactic vaccine adjuvants and their determinant role in new vaccine formulations. <i>Brazilian Journal of Medical and Biological Research</i> , 2012, 45, 681-692.	0.7	43
108	Enhancing and Tailoring the Immunogenicity of Vaccines with Novel Adjuvants. , 2012, , 45-72.		0
109	Distinct TLR adjuvants differentially stimulate systemic and local innate immune responses in nonhuman primates. <i>Blood</i> , 2012, 119, 2044-2055.	0.6	140
110	Self-Assembled Peptide Amphiphile Micelles Containing a Cytotoxic T Cell Epitope Promote a Protective Immune Response In Vivo. <i>Advanced Materials</i> , 2012, 24, 3845-3849.	11.1	207
111	A new synthetic TLR4 agonist, GLA, allows dendritic cells targeted with antigen to elicit Th1 T cell immunity in vivo. <i>European Journal of Immunology</i> , 2012, 42, 101-109.	1.6	69

#	ARTICLE	IF	CITATIONS
112	Prophylactic and therapeutic implications of toll-like receptor ligands. <i>Medicinal Research Reviews</i> , 2012, 32, 294-325.	5.0	60
113	Introduction to Vaccines and Adjuvants. , 2013, , 213-224.		2
114	Adjuvants containing natural and synthetic Toll-like receptor 4 ligands. <i>Expert Review of Vaccines</i> , 2013, 12, 793-807.	2.0	26
115	Self-Adjuvanting Polymer-Peptide Conjugates As Therapeutic Vaccine Candidates against Cervical Cancer. <i>Biomacromolecules</i> , 2013, 14, 2798-2806.	2.6	112
116	Carbon nanotubes as vaccine scaffolds. <i>Advanced Drug Delivery Reviews</i> , 2013, 65, 2016-2022.	6.6	62
117	Clinical vaccine development for H5N1 influenza. <i>Expert Review of Vaccines</i> , 2013, 12, 767-777.	2.0	24
118	Polymeric nanogels as vaccine delivery systems. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2013, 9, 159-173.	1.7	104
119	Immunization with a Chimera Consisting of the B Subunit of Shiga Toxin Type 2 and Brucella Lumazine Synthase Confers Total Protection against Shiga Toxins in Mice. <i>Journal of Immunology</i> , 2013, 191, 2403-2411.	0.4	45
120	Formulation Approaches and Strategies for Vaccines and Adjuvants. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2013, , 145-164.	0.2	1
121	Optimizing manufacturing and composition of a TLR4 nanosuspension: physicochemical stability and vaccine adjuvant activity. <i>Journal of Nanobiotechnology</i> , 2013, 11, 43.	4.2	8
122	Future directions for the development of Chlamydomonas-based vaccines. <i>Expert Review of Vaccines</i> , 2013, 12, 1011-1019.	2.0	17
123	Vaccine delivery carriers: Insights and future perspectives. <i>International Journal of Pharmaceutics</i> , 2013, 440, 27-38.	2.6	106
124	Characterization of chemically defined poly-N-isopropylacrylamide based copolymeric adjuvants. <i>Vaccine</i> , 2013, 31, 3519-3527.	1.7	12
125	Oral delivery of bioencapsulated exendin-4 expressed in chloroplasts lowers blood glucose level in mice and stimulates insulin secretion in beta-TC6 cells. <i>Plant Biotechnology Journal</i> , 2013, 11, 77-86.	4.1	84
126	Expression of Human Rotavirus Chimeric Fusion Proteins from Replicating but Non Disseminating Adenovectors and Elicitation of Rotavirus-Specific Immune Responses in Mice. <i>Molecular Biotechnology</i> , 2013, 54, 1010-1020.	1.3	4
127	Micro/nanoparticle adjuvants for antileishmanial vaccines: Present and future trends. <i>Vaccine</i> , 2013, 31, 735-749.	1.7	70
128	pH-Responsive Nanoparticle Vaccines for Dual-Delivery of Antigens and Immunostimulatory Oligonucleotides. <i>ACS Nano</i> , 2013, 7, 3912-3925.	7.3	280
129	New technologies in developing recombinant attenuated Salmonella vaccine vectors. <i>Microbial Pathogenesis</i> , 2013, 58, 17-28.	1.3	68

#	ARTICLE	IF	CITATIONS
130	Mesoporous silica nanoparticles as antigen carriers and adjuvants for vaccine delivery. <i>Nanoscale</i> , 2013, 5, 5167.	2.8	206
131	RNA: The new revolution in nucleic acid vaccines. <i>Seminars in Immunology</i> , 2013, 25, 152-159.	2.7	155
132	A human-derived protein SBP (HBsAg-binding protein) can bind to hepatitis B virus surface antigen (HBsAg) and enhance the immune response to hepatitis B virus (HBV) vaccine. <i>Molecular Immunology</i> , 2013, 53, 60-71.	1.0	10
133	Malaria Vaccine Adjuvants: Latest Update and Challenges in Preclinical and Clinical Research. <i>BioMed Research International</i> , 2013, 2013, 1-19.	0.9	35
134	Rationale, progress and development of vaccines utilizing STING-activating cyclic dinucleotide adjuvants. <i>Therapeutic Advances in Vaccines</i> , 2013, 1, 131-143.	2.7	155
135	Advances in the study of HLA-restricted epitope vaccines. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 2566-2577.	1.4	44
136	CCL19 and CCL28 Augment Mucosal and Systemic Immune Responses to HIV-1 gp140 by Mobilizing Responsive Immunocytes into Secondary Lymph Nodes and Mucosal Tissue. <i>Journal of Immunology</i> , 2013, 191, 1935-1947.	0.4	43
137	Unlipidated Outer Membrane Protein Omp16 (U-Omp16) from <i>Brucella</i> spp. as Nasal Adjuvant Induces a Th1 Immune Response and Modulates the Th2 Allergic Response to Cow's Milk Proteins. <i>PLoS ONE</i> , 2013, 8, e69438.	1.1	19
138	Construction of Monophosphoryl Lipid A Producing <i>Escherichia coli</i> Mutants and Comparison of Immuno-Stimulatory Activities of Their Lipopolysaccharides. <i>Marine Drugs</i> , 2013, 11, 363-376.	2.2	37
139	A Prime-Pull Vaccine Strategy Has a Modest Effect on Local and Systemic Antibody Responses to HIV gp140 in Mice. <i>PLoS ONE</i> , 2013, 8, e80559.	1.1	19
140	In Vivo and In Vitro Characterization of the Immune Stimulating Activity of the Neisserial Porin PorB. <i>PLoS ONE</i> , 2013, 8, e82171.	1.1	16
141	<i>Bacillus subtilis</i> Spores as Vaccine Adjuvants: Further Insights into the Mechanisms of Action. <i>PLoS ONE</i> , 2014, 9, e87454.	1.1	41
142	Current advancements and potential strategies in the development of MERS-CoV vaccines. <i>Expert Review of Vaccines</i> , 2014, 13, 761-774.	2.0	139
143	Chitosan. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 797-807.	1.4	118
144	Applications of immunochemistry in human health: advances in vaccinology and antibody design (IUPAC Technical Report). <i>Pure and Applied Chemistry</i> , 2014, 86, 1573-1617.	0.9	3
145	Structure, Size, and Solubility of Antigen Arrays Determines Efficacy in Experimental Autoimmune Encephalomyelitis. <i>AAPS Journal</i> , 2014, 16, 1185-1193.	2.2	26
146	Cellulose acetate phthalate microparticles containing <i>Vibrio cholerae</i> : steps toward an oral cholera vaccine. <i>Journal of Drug Targeting</i> , 2014, 22, 478-487.	2.1	17
147	Conserved immunogens in prime-boost strategies for the next-generation HIV-1 vaccines. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 601-616.	1.4	57

#	ARTICLE	IF	CITATIONS
148	Immune response in nasopharynx, lung, and blood elicited by experimental nasal pneumococcal vaccines containing live or heat-killed lactobacilli as mucosal adjuvants. <i>Canadian Journal of Physiology and Pharmacology</i> , 2014, 92, 124-131.	0.7	8
149	The basics and advances of immunomodulators and antigen presentation: a key to development of potent memory response against pathogens. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 1383-1397.	1.4	2
150	Functional and immunological evaluation of two novel proteins of <i>Leptospira</i> spp.. <i>Microbiology (United Kingdom)</i> , 2014, 160, 149-164.	0.7	25
151	Laser vaccine adjuvants. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 1892-1907.	1.4	38
152	A novel adjuvant, the mixture of alum and naltrexone, augments vaccine-induced immunity against <i>Plasmodium berghei</i> . <i>Immunological Investigations</i> , 2014, 43, 653-666.	1.0	11
153	Intranasal immunization with influenza antigens conjugated with cholera toxin subunit B stimulates broad spectrum immunity against influenza viruses. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 1211-1220.	1.4	18
154	Repeated dose toxicity study of <i>Vibrio cholerae</i> -loaded gastro-resistant microparticles. <i>Journal of Microencapsulation</i> , 2014, 31, 86-92.	1.2	9
155	Comparison of multiple adjuvants on the stability and immunogenicity of a clade C HIV-1 gp140 trimer. <i>Vaccine</i> , 2014, 32, 2109-2116.	1.7	27
156	The path of malaria vaccine development: challenges and perspectives. <i>Journal of Internal Medicine</i> , 2014, 275, 456-466.	2.7	88
157	Elimination of the cold-chain dependence of a nanoemulsion adjuvanted vaccine against tuberculosis by lyophilization. <i>Journal of Controlled Release</i> , 2014, 177, 20-26.	4.8	51
158	Nanoparticle Adjuvant Sensing by TLR7 Enhances CD8+ T Cell-Mediated Protection from <i>Listeria Monocytogenes</i> Infection. <i>Journal of Immunology</i> , 2014, 192, 1071-1078.	0.4	54
159	Biomaterials for Nanoparticle Vaccine Delivery Systems. <i>Pharmaceutical Research</i> , 2014, 31, 2563-2582.	1.7	258
161	Silica vesicles as nanocarriers and adjuvants for generating both antibody and T-cell mediated immune responses to Bovine Viral Diarrhoea Virus E2 protein. <i>Biomaterials</i> , 2014, 35, 9972-9983.	5.7	37
162	Time course study of the antigen-specific immune response to a PLGA microparticle vaccine formulation. <i>Biomaterials</i> , 2014, 35, 8385-8393.	5.7	58
163	Discovering a vaccine against neosporosis using computers: is it feasible?. <i>Trends in Parasitology</i> , 2014, 30, 401-411.	1.5	28
164	Combining Viral Vected and Protein-in-adjuvant Vaccines Against the Blood-stage Malaria Antigen AMA1: Report on a Phase 1a Clinical Trial. <i>Molecular Therapy</i> , 2014, 22, 2142-2154.	3.7	68
165	Platycodon grandiflorum polysaccharide induces dendritic cell maturation via TLR4 signaling. <i>Food and Chemical Toxicology</i> , 2014, 72, 212-220.	1.8	55
166	Dendritic cell-targeted vaccines – hope or hype?. <i>Nature Reviews Immunology</i> , 2014, 14, 705-711.	10.6	189

#	ARTICLE	IF	CITATIONS
167	Enhanced Humoral and Cell-Mediated Immune Responses Generated by Cationic Polymer-Coated PLA Microspheres with Adsorbed HBsAg. <i>Molecular Pharmaceutics</i> , 2014, 11, 1772-1784.	2.3	85
168	Immunoadjuvant Efficacy of <i>N</i> -Carboxymethyl Chitosan for Vaccination via Dendritic Cell Activation. <i>Journal of Medicinal Food</i> , 2014, 17, 268-277.	0.8	13
169	Maximal immune response and cross protection by influenza virus nucleoprotein derived from <i>E. coli</i> using an optimized formulation. <i>Virology</i> , 2014, 468-470, 265-273.	1.1	8
170	Enhanced in Vivo Targeting of Murine Nonparenchymal Liver Cells with Monophosphoryl Lipid A Functionalized Microcapsules. <i>Biomacromolecules</i> , 2014, 15, 2378-2388.	2.6	15
171	<i>In Vitro</i> Assembly of the Outer Core of the Lipopolysaccharide from <i>Escherichia coli</i> K-12 and <i>Salmonella typhimurium</i> . <i>Biochemistry</i> , 2014, 53, 1250-1262.	1.2	30
172	Immunological principles regulating immunomodulation with biomaterials. <i>Acta Biomaterialia</i> , 2014, 10, 1720-1727.	4.1	17
173	Adjuvant effect of polysaccharide from fruits of <i>Physalis alkekengi</i> L. in DNA vaccine against systemic candidiasis. <i>Carbohydrate Polymers</i> , 2014, 109, 77-84.	5.1	24
174	Development of a minimal saponin vaccine adjuvant based on QS-21. <i>Nature Chemistry</i> , 2014, 6, 635-643.	6.6	68
175	Enhanced dendritic cell maturation by the B-chain of Korean mistletoe lectin (KML-B), a novel TLR4 agonist. <i>International Immunopharmacology</i> , 2014, 21, 309-319.	1.7	34
176	Disintegration and cancer immunotherapy efficacy of a squalane-in-water delivery system emulsified by bioresorbable poly(ethylene glycol)-block-poly(lactide). <i>Biomaterials</i> , 2014, 35, 1686-1695.	5.7	27
178	Subcutaneous immunization with a novel immunogenic candidate (urease) confers protection against <i>Brucella abortus</i> and <i>Brucella melitensis</i> infections. <i>Apmis</i> , 2015, 123, 667-675.	0.9	17
179	Overall conceptual framework for studying the genetics of autoimmune diseases following vaccination: a regulatory perspective. <i>Biomarkers in Medicine</i> , 2015, 9, 1107-1120.	0.6	2
180	Induction of Potent Antitumor Immunity by Sustained Release of Cationic Antigen from a DNA-Based Hydrogel with Adjuvant Activity. <i>Advanced Functional Materials</i> , 2015, 25, 5758-5767.	7.8	79
181	Administration of naloxone in combination with recombinant <i>Plasmodium vivax</i> AMA-1 in BALB/c mice induces mixed Th1/Th2 immune responses. <i>Parasite Immunology</i> , 2015, 37, 521-532.	0.7	6
182	Small Wonders—The Use of Nanoparticles for Delivering Antigen. <i>Vaccines</i> , 2015, 3, 638-661.	2.1	27
183	Recent Advances of Vaccine Adjuvants for Infectious Diseases. <i>Immune Network</i> , 2015, 15, 51.	1.6	312
184	The Adjuvant Activity of <i>Epimedium</i> Polysaccharide-Propolis Flavone Liposome on Enhancing Immune Responses to Inactivated Porcine Circovirus Vaccine in Mice. <i>Evidence-based Complementary and Alternative Medicine</i> , 2015, 2015, 1-9.	0.5	14
185	Nanoengineering of vaccines using natural polysaccharides. <i>Biotechnology Advances</i> , 2015, 33, 1279-1293.	6.0	96

#	ARTICLE	IF	CITATIONS
186	Intranasal and oral vaccination with protein-based antigens: advantages, challenges and formulation strategies. <i>Protein and Cell</i> , 2015, 6, 480-503.	4.8	115
187	The mechanisms of action of vaccines containing aluminum adjuvants: an in vitro vs in vivo paradigm. SpringerPlus, 2015, 4, 181.	1.2	119
188	Beyond adjuvants: Antagonizing inflammation to enhance vaccine immunity. <i>Vaccine</i> , 2015, 33, B55-B59.	1.7	35
189	Induction of Potent Adaptive Immunity by the Novel Polyion Complex Nanoparticles. <i>Vaccine Journal</i> , 2015, 22, 578-585.	3.2	5
190	Herbal plant-derived compound, 1,2,3,4,6-penta-O-galloyl- β -D-glucose, increases cross-presentation by dendritic cells. <i>Traditional & Kampo Medicine</i> , 2015, 2, 43-49.	0.2	1
191	Chitosan-based mucosal adjuvants: Sunrise on the ocean. <i>Vaccine</i> , 2015, 33, 5997-6010.	1.7	76
192	Cationic micelle delivery of Trp2 peptide for efficient lymphatic draining and enhanced cytotoxic T-lymphocyte responses. <i>Journal of Controlled Release</i> , 2015, 200, 1-12.	4.8	84
193	Interleukin/chitosan (JY) adjuvant enhances the mucosal immunity of human papillomavirus 16 L1 virus-like particles in mice. <i>Biotechnology Letters</i> , 2015, 37, 773-777.	1.1	6
194	Mimicking microbial strategies for the design of mucus-permeating nanoparticles for oral immunization. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2015, 96, 454-463.	2.0	30
195	Efficacy of a trans-sialidase-ISCOMATRIX subunit vaccine candidate to protect against experimental Chagas disease. <i>Vaccine</i> , 2015, 33, 1274-1283.	1.7	38
196	Comparative analysis of the molecular adjuvants and their binding efficiency with CR1. <i>Interdisciplinary Sciences, Computational Life Sciences</i> , 2015, 8, 35.	2.2	0
197	Gold nanoparticles and vaccine development. <i>Expert Review of Vaccines</i> , 2015, 14, 1197-1211.	2.0	69
198	Functional analysis of bovine TLR5 and association with IgA responses of cattle following systemic immunisation with H7 flagella. <i>Veterinary Research</i> , 2015, 46, 9.	1.1	17
199	Oral administration of recombinant <i>Neisseria meningitidis</i> PorA genetically fused to <i>H. pylori</i> HpaA antigen increases antibody levels in mouse serum, suggesting that PorA behaves as a putative adjuvant. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 776-788.	1.4	6
200	A bacterial protease inhibitor protects antigens delivered in oral vaccines from digestion while triggering specific mucosal immune responses. <i>Journal of Controlled Release</i> , 2015, 220, 18-28.	4.8	28
201	Comparing Antibody Responses in Chickens Against <i>Plasmodium falciparum</i> Lactate Dehydrogenase and Glyceraldehyde-3-phosphate Dehydrogenase with Freund's and Pheroid Adjuvants. <i>Immunological Investigations</i> , 2015, 44, 627-642.	1.0	8
202	Umbilical cord blood-derived dendritic cells infected by adenovirus for SP17 expression induce antigen-specific cytotoxic T cells against NSCLC cells. <i>Cellular Immunology</i> , 2015, 298, 18-24.	1.4	7
203	Evaluation of the immunogenicity and protective efficacy of Killed <i>Leishmania donovani</i> antigen along with different adjuvants against experimental visceral leishmaniasis. <i>Medical Microbiology and Immunology</i> , 2015, 204, 539-550.	2.6	8

#	ARTICLE	IF	CITATIONS
204	Cancer vaccine adjuvants – recent clinical progress and future perspectives. <i>Immunopharmacology and Immunotoxicology</i> , 2015, 37, 1-11.	1.1	88
205	Is There an Optimal Formulation and Delivery Strategy for Subunit Vaccines?. <i>Pharmaceutical Research</i> , 2016, 33, 2078-2097.	1.7	58
206	Stimulation of In Vivo Antitumor Immunity with Hollow Mesoporous Silica Nanospheres. <i>Angewandte Chemie - International Edition</i> , 2016, 55, 1899-1903.	7.2	116
207	Conjugation with an Inulin-Chitosan Adjuvant Markedly Improves the Immunogenicity of <i>Mycobacterium tuberculosis</i> CFP10-TB10.4 Fusion Protein. <i>Molecular Pharmaceutics</i> , 2016, 13, 3626-3635.	2.3	23
208	In silico designing of some agonists of toll-like receptor 5 as a novel vaccine adjuvant candidates. <i>Network Modeling Analysis in Health Informatics and Bioinformatics</i> , 2016, 5, 1.	1.2	12
209	The genetic background influences the cellular and humoral immune responses to vaccines. <i>Clinical and Experimental Immunology</i> , 2016, 186, 190-204.	1.1	19
210	Chemical Synthesis, Versatile Structures and Functions of Tailorable Adjuvants for Optimizing Oral Vaccination. <i>ACS Applied Materials & Interfaces</i> , 2016, 8, 34933-34950.	4.0	11
211	A Lipid Based Antigen Delivery System Efficiently Facilitates MHC Class-I Antigen Presentation in Dendritic Cells to Stimulate CD8+ T Cells. <i>Scientific Reports</i> , 2016, 6, 27206.	1.6	46
212	Oral exposure to mineral oils: Is there an association with immune perturbation and autoimmunity?. <i>Toxicology</i> , 2016, 344-346, 19-25.	2.0	6
213	Combination of the toll like receptor agonist and β -Galactosylceramide as an efficient adjuvant for cancer vaccine. <i>Journal of Biomedical Science</i> , 2016, 23, 16.	2.6	37
214	Universal influenza vaccine design: directing the antibody repertoire. <i>Future Virology</i> , 2016, 11, 451-467.	0.9	2
215	Protection and Long-Lived Immunity Induced by the ID93/GLA-SE Vaccine Candidate against a Clinical <i>Mycobacterium tuberculosis</i> Isolate. <i>Vaccine Journal</i> , 2016, 23, 137-147.	3.2	41
216	Double conjugation strategy to incorporate lipid adjuvants into multiantigenic vaccines. <i>Chemical Science</i> , 2016, 7, 2308-2321.	3.7	24
217	Controlled and targeted release of antigens by intelligent shell for improving applicability of oral vaccines. <i>Biomaterials</i> , 2016, 77, 307-319.	5.7	51
218	Comparative Analysis of the Molecular Adjuvants and Their Binding Efficiency with CR1. <i>Interdisciplinary Sciences, Computational Life Sciences</i> , 2016, 8, 35-40.	2.2	3
219	Submicron-sized hydrogels incorporating cyclic dinucleotides for selective delivery and elevated cytokine release in macrophages. <i>Acta Biomaterialia</i> , 2016, 29, 271-281.	4.1	39
220	Stimulation of In Vivo Antitumor Immunity with Hollow Mesoporous Silica Nanospheres. <i>Angewandte Chemie</i> , 2016, 128, 1931-1935.	1.6	19
221	Recent advances in self-assembled peptides: Implications for targeted drug delivery and vaccine engineering. <i>Advanced Drug Delivery Reviews</i> , 2017, 110-111, 169-187.	6.6	281

#	ARTICLE	IF	CITATIONS
222	Efficacy of Phase 3 Trial of RTS, S/AS01 Malaria Vaccine in infants: a systematic review and meta-analysis. <i>Human Vaccines and Immunotherapeutics</i> , 2017, , 00-00.	1.4	6
223	Enhancement of antigen-specific CD4+ and CD8+ T cell responses using a self-assembled biologic nanolipoprotein particle vaccine. <i>Vaccine</i> , 2017, 35, 1475-1481.	1.7	15
224	Alum adjuvanted rabies DNA vaccine confers 80% protection against lethal 50 LD50 rabies challenge virus standard strain. <i>Molecular Immunology</i> , 2017, 85, 166-173.	1.0	15
225	A Modular Antigen Presenting Peptide/Oligonucleotide Nanostructure Platform for Inducing Potent Immune Response. <i>Advanced Biology</i> , 2017, 1, e1700015.	3.0	5
226	Use of adjuvants for immunotherapy. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 1774-1777.	1.4	27
227	Gene transfection efficiency into dendritic cells is influenced by the size of cationic liposomes/DNA complexes. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 102, 230-236.	1.9	34
228	Efficient induction of comprehensive immune responses to control pathogenic <i>E. coli</i> by clay nano-adjuvant with the moderate size and surface charge. <i>Scientific Reports</i> , 2017, 7, 13367.	1.6	23
229	Combining R-DOTAP and a particulate antigen delivery platform to trigger dendritic cell activation: Formulation development and in-vitro interaction studies. <i>International Journal of Pharmaceutics</i> , 2017, 532, 37-46.	2.6	10
230	Structure–function relationships of protein–lipopeptide complexes and influence on immunogenicity. <i>Amino Acids</i> , 2017, 49, 1691-1704.	1.2	9
231	Development and assessment of a new cage-like particle adjuvant. <i>Journal of Pharmacy and Pharmacology</i> , 2017, 69, 1293-1303.	1.2	22
232	Calcium phosphate nanoparticles as a new generation vaccine adjuvant. <i>Expert Review of Vaccines</i> , 2017, 16, 895-906.	2.0	59
233	Liposomal adjuvant development for leishmaniasis vaccines. <i>Therapeutic Advances in Vaccines</i> , 2017, 5, 85-101.	2.7	21
234	New perspectives for natural triterpene glycosides as potential adjuvants. <i>Phytomedicine</i> , 2017, 37, 49-57.	2.3	23
235	A Powerful CD8 ⁺ T Cell Stimulating Tetrapeptide Hydrogel as a Very Promising Vaccine Adjuvant. <i>Advanced Materials</i> , 2017, 29, 1601776.	11.1	198
236	Syntheses and mucosal adjuvant activity of simplified oleanolic acid saponins possessing cinnamoyl ester. <i>Bioorganic and Medicinal Chemistry</i> , 2017, 25, 1747-1755.	1.4	14
237	Modular Peptide Amphiphile Micelles Improving an Antibody-Mediated Immune Response to Group A Streptococcus. <i>ACS Biomaterials Science and Engineering</i> , 2017, 3, 144-152.	2.6	34
238	U-Omp19 from <i>Brucella abortus</i> Is a Useful Adjuvant for Vaccine Formulations against Salmonella Infection in Mice. <i>Frontiers in Immunology</i> , 2017, 8, 171.	2.2	30
239	Nanomaterials in the Context of Type 2 Immune Responses—Fears and Potentials. <i>Frontiers in Immunology</i> , 2017, 8, 471.	2.2	19

#	ARTICLE	IF	CITATIONS
240	Technological Microbiology: Development and Applications. <i>Frontiers in Microbiology</i> , 2017, 8, 827.	1.5	68
241	Oral immunization of mice with Omp31-loaded &N-trimethyl chitosan nanoparticles induces high protection against &Brucella melitensis infection. <i>International Journal of Nanomedicine</i> , 2017, Volume 12, 8769-8778.	3.3	43
242	Poly(I:C) adjuvant strongly enhances parasite-inhibitory antibodies and Th1 response against <i>Plasmodium falciparum</i> merozoite surface protein-1 (42-kDa fragment) in BALB/c mice. <i>Medical Microbiology and Immunology</i> , 2018, 207, 151-166.	2.6	10
243	Development and physicochemical, toxicity and immunogenicity assessments of recombinant hepatitis B surface antigen (rHBsAg) entrapped in chitosan and mannosylated chitosan nanoparticles: as a novel vaccine delivery system and adjuvant. <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2018, 46, 230-240.	1.9	27
244	Squalene containing solid lipid nanoparticles, a promising adjuvant system for yeast vaccines. <i>Vaccine</i> , 2018, 36, 2314-2320.	1.7	14
245	Adjuvants for Animal Vaccines. <i>Viral Immunology</i> , 2018, 31, 11-22.	0.6	67
246	Effective antigen delivery via dual entrapment in erythrocytes and autologous plasma beads. <i>Journal of Drug Targeting</i> , 2018, 26, 162-171.	2.1	3
247	<i>Bacillus toyonensis</i> improves immune response in the mice vaccinated with recombinant antigen of bovine herpesvirus type 5. <i>Beneficial Microbes</i> , 2018, 9, 133-142.	1.0	15
248	3M&O52 as an adjuvant for a PLGA microparticle&b based <i>Leishmania donovani</i> recombinant protein vaccine. <i>Journal of Biomedical Materials Research - Part B Applied Biomaterials</i> , 2018, 106, 1587-1594.	1.6	9
249	Clay Nanoparticles Elicit Long&Term Immune Responses by Forming Biodegradable Depots for Sustained Antigen Stimulation. <i>Small</i> , 2018, 14, e1704465.	5.2	53
250	Comparison of immunogenical potency of <i>Leishmania major</i> (MRHO/IR/75/ER) antigens prepared by 3 different methods in conjunction with Alum-Naltrexone adjuvant in BALB/c mice. <i>Alexandria Journal of Medicine</i> , 2018, 54, 503-510.	0.4	9
251	The Mevalonate Pathway Is a Druggable Target for Vaccine Adjuvant Discovery. <i>Cell</i> , 2018, 175, 1059-1073.e21.	13.5	148
252	Polyglutamic acid-trimethyl chitosan-based intranasal peptide nano-vaccine induces potent immune responses against group A streptococcus. <i>Acta Biomaterialia</i> , 2018, 80, 278-287.	4.1	75
253	Biomaterials for vaccine-based cancer immunotherapy. <i>Journal of Controlled Release</i> , 2018, 292, 256-276.	4.8	146
254	Potential Hepatitis B Vaccine Formulation Prepared by Uniform-Sized Lipid Hybrid PLA Microparticles with Adsorbed Hepatitis B Surface Antigen. <i>Molecular Pharmaceutics</i> , 2018, 15, 5227-5235.	2.3	10
255	Oral vaccine based on a surface immunogenic protein mixed with alum promotes a decrease in <i>Streptococcus agalactiae</i> vaginal colonization in a mouse model. <i>Molecular Immunology</i> , 2018, 103, 63-70.	1.0	8
256	Antigen uptake and immunoadjuvant activity of pathogen-mimetic hollow silica particles conjugated with I ² -glucan. <i>Journal of Materials Chemistry B</i> , 2018, 6, 6288-6301.	2.9	8
257	Understanding how combinatorial targeting of TLRs and TNFR family costimulatory members promote enhanced T cell responses. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 1073-1083.	1.4	1

#	ARTICLE	IF	CITATIONS
258	Institutional shaping of research priorities: A case study on avian influenza. <i>Research Policy</i> , 2018, 47, 1975-1989.	3.3	31
259	Peptide-based vaccines. , 2018, , 327-358.		28
260	CD22-Binding Synthetic Sialosides Regulate B Lymphocyte Proliferation Through CD22 Ligand-Dependent and Independent Pathways, and Enhance Antibody Production in Mice. <i>Frontiers in Immunology</i> , 2018, 9, 820.	2.2	25
261	Bilayer polymeric nanocapsules: A formulation approach for a thermostable and adjuvanted <i>E. coli</i> antigen vaccine. <i>Journal of Controlled Release</i> , 2018, 286, 20-32.	4.8	30
262	Gamma irradiation of <i>Toxoplasma gondii</i> protein extract improve immune response and protection in mice models. <i>Biomedicine and Pharmacotherapy</i> , 2018, 106, 599-604.	2.5	13
263	Properties and applications of nanoparticle/microparticle conveyors with adjuvant characteristics suitable for oral vaccination. <i>International Journal of Nanomedicine</i> , 2018, Volume 13, 2973-2987.	3.3	24
264	Th1 immune response to <i>Plasmodium falciparum</i> recombinant thrombospondin-related adhesive protein (TRAP) antigen is enhanced by TLR3-specific adjuvant, poly(I:C) in BALB/c mice. <i>Parasite Immunology</i> , 2018, 40, e12538.	0.7	8
265	Vaccine adjuvants CpG (oligodeoxynucleotides ODNs), MPL (3-O-deacylated monophosphoryl lipid A) and naloxone-enhanced Th1 immune response to the <i>Plasmodium vivax</i> recombinant thrombospondin-related adhesive protein (TRAP) in mice. <i>Medical Microbiology and Immunology</i> , 2018, 207, 271-286.	2.6	7
266	Nanohydrogels. , 2018, , 293-368.		13
267	Broad and systemic immune-modulating capacity of plant-derived dsRNA. <i>International Immunology</i> , 2019, 31, 811-821.	1.8	1
268	Development of Universal Influenza Vaccines Targeting Conserved Viral Proteins. <i>Vaccines</i> , 2019, 7, 169.	2.1	25
269	Antigen-Specific Mucosal Immunity Regulates Development of Intestinal Bacteria-Mediated Diseases. <i>Gastroenterology</i> , 2019, 157, 1530-1543.e4.	0.6	24
270	Injectable Polypeptide Hydrogel Depot System for Assessment of the Immune Response—Inducing Efficacy of Sustained Antigen Release Alone. <i>Macromolecular Bioscience</i> , 2019, 19, 1900167.	2.1	10
271	Nanoemulsions: Factory for Food, Pharmaceutical and Cosmetics. <i>Processes</i> , 2019, 7, 617.	1.3	129
272	Up-to-date vaccine delivery systems: robust immunity elicited by multifarious nanomaterials upon administration through diverse routes. <i>Biomaterials Science</i> , 2019, 7, 822-835.	2.6	22
273	Adjuvant Allergen Fusion Proteins as Novel Tools for the Treatment of Type I Allergies. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2019, 67, 273-293.	1.0	6
274	Phosphorothioated antisense oligodeoxynucleotide suppressing interleukin-10 is a safe and potent vaccine adjuvant. <i>Vaccine</i> , 2019, 37, 4081-4088.	1.7	5
275	Chemical and Immunological Characteristics of Aluminum-Based, Oil-Water Emulsion, and Bacterial-Origin Adjuvants. <i>Journal of Immunology Research</i> , 2019, 2019, 1-9.	0.9	21

#	ARTICLE	IF	CITATIONS
276	Changing the Interface Between an Asphaltene Model Compound and Water by Addition of an EO-PO Demulsifier through Adsorption Competition or Adsorption Replacement. <i>Energy & Fuels</i> , 2019, 33, 5035-5042.	2.5	23
277	Biodegradable polymers for modern vaccine development. <i>Journal of Industrial and Engineering Chemistry</i> , 2019, 77, 12-24.	2.9	43
278	Chitosan-based nanoparticles: promising biomedical applications in specific drug delivery and targeting. , 2019, , 215-257.		2
279	Adjuvanticity of aqueous extracts of <i>Artemisia rupestris</i> L. for inactivated foot-and-mouth disease vaccine in mice. <i>Research in Veterinary Science</i> , 2019, 124, 191-199.	0.9	11
280	Chitosan Plus Compound 48/80: Formulation and Preliminary Evaluation as a Hepatitis B Vaccine Adjuvant. <i>Pharmaceutics</i> , 2019, 11, 72.	2.0	29
281	The Combination Vaccine Adjuvant System Alum/c-di-AMP Results in Quantitative and Qualitative Enhanced Immune Responses Post Immunization. <i>Frontiers in Cellular and Infection Microbiology</i> , 2019, 9, 31.	1.8	30
282	TLR9 agonist enhances radiofrequency ablation-induced CTL responses, leading to the potent inhibition of primary tumor growth and lung metastasis. <i>Cellular and Molecular Immunology</i> , 2019, 16, 820-832.	4.8	37
283	Vaccines for leishmaniasis and the implications of their development for American tegumentary leishmaniasis. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 919-930.	1.4	22
284	Allopurinol therapy provides long term clinical improvement, but additional immunotherapy is required for sustained parasite clearance, in <i>L. infantum</i> -infected dogs. <i>Vaccine: X</i> , 2020, 4, 100048.	0.9	11
285	Immune-mediated approaches against COVID-19. <i>Nature Nanotechnology</i> , 2020, 15, 630-645.	15.6	260
286	Immune modulatory capacity of probiotic lactic acid bacteria and applications in vaccine development. <i>Beneficial Microbes</i> , 2020, 11, 213-226.	1.0	22
287	The Perspective on Bio-Nano Interface Technology for Covid-19. <i>Frontiers in Nanotechnology</i> , 2020, 2, .	2.4	12
288	Plant-based vaccines and antibodies to combat COVID-19: current status and prospects. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 2913-2920.	1.4	39
289	Rational Design of Antigen Incorporation Into Subunit Vaccine Biomaterials Can Enhance Antigen-Specific Immune Responses. <i>Frontiers in Immunology</i> , 2020, 11, 1547.	2.2	15
290	A New Cage-Like Particle Adjuvant Enhances Protection of Foot-and-Mouth Disease Vaccine. <i>Frontiers in Veterinary Science</i> , 2020, 7, 396.	0.9	8
291	Phototherapy as a Rational Antioxidant Treatment Modality in COVID-19 Management; New Concept and Strategic Approach: Critical Review. <i>Antioxidants</i> , 2020, 9, 875.	2.2	21
292	Association of <i>Bacillus toyonensis</i> spores with alum improves bovine herpesvirus 5 subunit vaccine immune response in mice. <i>Vaccine</i> , 2020, 38, 8216-8223.	1.7	2
293	MERS-CoV Spike Protein Vaccine and Inactivated Influenza Vaccine Formulated with Single Strand RNA Adjuvant Induce T-Cell Activation through Intranasal Immunization in Mice. <i>Pharmaceutics</i> , 2020, 12, 441.	2.0	10

#	ARTICLE	IF	CITATIONS
294	Comparative study of α -helical and β -sheet self-assembled peptide nanofiber vaccine platforms: influence of integrated T-cell epitopes. <i>Biomaterials Science</i> , 2020, 8, 3522-3535.	2.6	35
295	<i>Bacillus subtilis</i> spores as adjuvants against avian influenza H9N2 induce antigen-specific antibody and T cell responses in White Leghorn chickens. <i>Veterinary Research</i> , 2020, 51, 68.	1.1	20
296	Organic/inorganic nanocomposites for cancer immunotherapy. <i>Materials Chemistry Frontiers</i> , 2020, 4, 2571-2609.	3.2	38
297	Characterization of <i>Bacillus anthracis</i> Spore Proteins Using a Nanoscaffold Vaccine Platform. <i>Frontiers in Immunology</i> , 2020, 11, 1264.	2.2	4
298	An insight into the epitope-based peptide vaccine design strategy and studies against COVID-19. <i>Turkish Journal of Biology</i> , 2020, 44, 215-227.	2.1	24
299	Microfluidic-prepared DOTAP nanoparticles induce strong T-cell responses in mice. <i>PLoS ONE</i> , 2020, 15, e0227891.	1.1	12
300	Mechanisms of Mixed Th1/Th2 Responses in Mice Induced by <i>Albizia julibrissin</i> Saponin Active Fraction by in Silico Analysis. <i>Vaccines</i> , 2020, 8, 48.	2.1	7
301	SARS-CoV-2: an unknown agent and challenges in vaccine development. <i>Journal of Bio-X Research</i> , 2020, 3, 3-5.	0.3	1
302	SARS-CoV-2 vaccine research and development: Conventional vaccines and biomimetic nanotechnology strategies. <i>Asian Journal of Pharmaceutical Sciences</i> , 2021, 16, 136-146.	4.3	24
303	Bioengineering of nano metal-organic frameworks for cancer immunotherapy. <i>Nano Research</i> , 2021, 14, 1244-1259.	5.8	37
304	A DNA nanodevice-based vaccine for cancer immunotherapy. <i>Nature Materials</i> , 2021, 20, 421-430.	13.3	320
305	Vaccine as immunotherapy for leishmaniasis. , 2021, , 29-46.		0
306	Mining of Ebola virus genome for the construction of multi-epitope vaccine to combat its infection. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 4815-4831.	2.0	9
307	An Overview on Chitosan-Based Adjuvant/Vaccine Delivery Systems. <i>Advances in Polymer Science</i> , 2021, , 293-379.	0.4	4
308	<i>Bacillus Toyonensis</i> BCT-7112T Spores as Parenteral Adjuvant of BoHV-5 Vaccine in a Murine Model. <i>Probiotics and Antimicrobial Proteins</i> , 2021, 13, 655-663.	1.9	2
309	<i>Staphylococcus aureus</i> and Dairy Udder. , 0, , .		1
310	TLR4 Agonist Combined with Trivalent Protein JointS of <i>Streptococcus suis</i> Provides Immunological Protection in Animals. <i>Vaccines</i> , 2021, 9, 184.	2.1	7
311	Nanoemulsions for health, food, and cosmetics: a review. <i>Environmental Chemistry Letters</i> , 2021, 19, 3381-3395.	8.3	101

#	ARTICLE	IF	CITATIONS
312	Polyphosphazenes as Adjuvants for Animal Vaccines and Other Medical Applications. <i>Frontiers in Bioengineering and Biotechnology</i> , 2021, 9, 625482.	2.0	13
313	Hyaluronan is a natural and effective immunological adjuvant for protein-based vaccines. <i>Cellular and Molecular Immunology</i> , 2021, 18, 1197-1210.	4.8	14
314	Protective effect of a DNA vaccine cocktail encoding ROP13 and GRA14 with Alum nano-adjuvant against <i>Toxoplasma gondii</i> infection in mice. <i>International Journal of Biochemistry and Cell Biology</i> , 2021, 132, 105920.	1.2	8
315	A review of combination adjuvants for malaria vaccines: a promising approach for vaccine development. <i>International Journal for Parasitology</i> , 2021, 51, 699-717.	1.3	8
316	Saponin-adjuvanted recombinant vaccines containing rCP00660, rCP09720 or rCP01850 proteins against <i>Corynebacterium pseudotuberculosis</i> infection in mice. <i>Vaccine</i> , 2021, 39, 2568-2574.	1.7	4
317	Lipid-Based Nanoparticles in the Clinic and Clinical Trials: From Cancer Nanomedicine to COVID-19 Vaccines. <i>Vaccines</i> , 2021, 9, 359.	2.1	222
318	The Adjuvant Effects on Vaccine and the Immunomodulatory Mechanisms of Polysaccharides From Traditional Chinese Medicine. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 655570.	1.6	22
319	Intranasal administration of a recombinant RBD vaccine induced protective immunity against SARS-CoV-2 in mouse. <i>Vaccine</i> , 2021, 39, 2280-2287.	1.7	47
320	Involvement of Interleukin-1 Receptor-Associated Kinase 4 and Interferon Regulatory Factor 5 in the Immunopathogenesis of SARS-CoV-2 Infection: Implications for the Treatment of COVID-19. <i>Frontiers in Immunology</i> , 2021, 12, 638446.	2.2	9
322	Recent Progress in the Design and Medical Application of In Situ Self-Assembled Polypeptide Materials. <i>Pharmaceutics</i> , 2021, 13, 753.	2.0	17
323	FMD empty capsids combined with the Immunostant Particle Adjuvant -ISPA or ISA206 induce protective immunity against foot and mouth disease virus. <i>Virus Research</i> , 2021, 297, 198339.	1.1	12
325	Microparticle encapsulation of a tuberculosis subunit vaccine candidate containing a nanoemulsion adjuvant via spray drying. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2021, 163, 23-37.	2.0	22
326	The Status and Prospects of Epstein-Barr Virus Prophylactic Vaccine Development. <i>Frontiers in Immunology</i> , 2021, 12, 677027.	2.2	23
327	In Vivo Sustained Release of Peptide Vaccine Mediated by Dendritic Mesoporous Silica Nanocarriers. <i>Frontiers in Immunology</i> , 2021, 12, 684612.	2.2	12
328	Nano and Microparticles as Potential Oral Vaccine Carriers and Adjuvants Against Infectious Diseases. <i>Frontiers in Pharmacology</i> , 2021, 12, 682286.	1.6	47
329	A Novel Recombinant Fc γ 3 Receptor-Targeted Survivin Combines with Chemotherapy for Efficient Cancer Treatment. <i>Biomedicines</i> , 2021, 9, 806.	1.4	5
330	Adjuvants: friends in vaccine formulations against infectious diseases. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 3539-3550.	1.4	7
331	Development of PDA Nanoparticles for H9N2 Avian Influenza BPP-V/BP-IV Epitope Peptide Vaccines: Immunogenicity and Delivery Efficiency Improvement. <i>Frontiers in Immunology</i> , 2021, 12, 693972.	2.2	3

#	ARTICLE	IF	CITATIONS
332	Administration of Multivalent Influenza Virus Recombinant Hemagglutinin Vaccine in Combination-Adjuvant Elicits Broad Reactivity Beyond the Vaccine Components. <i>Frontiers in Immunology</i> , 2021, 12, 692151.	2.2	13
333	Immunostimulatory effect of chitosan and quaternary chitosan: A review of potential vaccine adjuvants. <i>Carbohydrate Polymers</i> , 2021, 264, 118050.	5.1	67
334	Pore-forming alpha-hemolysin efficiently improves the immunogenicity and protective efficacy of protein antigens. <i>PLoS Pathogens</i> , 2021, 17, e1009752.	2.1	2
335	To Be or Not To Be Vaccinated: That Is a Question in Myasthenia Gravis. <i>Frontiers in Immunology</i> , 2021, 12, 733418.	2.2	20
336	In silico approach to design a multi-epitopic vaccine candidate targeting the non-mutational immunogenic regions in envelope protein and surface glycoprotein of SARS-CoV-2. <i>Journal of Biomolecular Structure and Dynamics</i> , 2021, , 1-16.	2.0	7
337	Combination of conserved recombinant proteins (NP & 3M2e) formulated with Alum protected BALB/c mice against influenza A/PR8/H1N1 virus challenge. <i>Biotechnology Letters</i> , 2021, 43, 2137-2147.	1.1	1
338	Monophosphoryl Lipid A and Poly I:C Combination Adjuvant Promoted Ovalbumin-Specific Cell Mediated Immunity in Mice Model. <i>Biology</i> , 2021, 10, 908.	1.3	5
339	Aqueous extracts from cultivated <i>Cistanche deserticola</i> Y.C. Ma as polysaccharide adjuvant promote immune responses via facilitating dendritic cell activation. <i>Journal of Ethnopharmacology</i> , 2021, 277, 114256.	2.0	9
340	The MAVS Immune Recognition Pathway in Viral Infection and Sepsis. <i>Antioxidants and Redox Signaling</i> , 2021, 35, 1376-1392.	2.5	24
341	Potential of nanoparticles encapsulated drugs for possible inhibition of the antimicrobial resistance development. <i>Biomedicine and Pharmacotherapy</i> , 2021, 141, 111943.	2.5	13
342	Distinct endocytosis and immune activation of poly(lactic-co-glycolic) acid nanoparticles prepared by single- and double-emulsion evaporation. <i>Nanomedicine</i> , 2021, 16, 2075-2094.	1.7	4
343	Immunoinformatics analysis of antigenic epitopes and designing of a multi-epitope peptide vaccine from putative nitro-reductases of <i>Mycobacterium tuberculosis</i> DosR. <i>Infection, Genetics and Evolution</i> , 2021, 94, 105017.	1.0	10
344	T helper type 1 biased immune responses by PPE17 loaded core-shell alginate-chitosan nanoparticles after subcutaneous and intranasal administration. <i>Life Sciences</i> , 2021, 282, 119806.	2.0	12
345	How can we develop an effective subunit vaccine to achieve successful malaria eradication?. <i>Microbial Pathogenesis</i> , 2021, 160, 105203.	1.3	6
346	Immunological perspectives on spatial and temporal vaccine delivery. <i>Advanced Drug Delivery Reviews</i> , 2021, 178, 113966.	6.6	14
347	Alum and metoclopramide synergistically enhance cellular and humoral immunity after immunization with heat-killed <i>Salmonella typhimurium</i> vaccine. <i>International Immunopharmacology</i> , 2021, 101, 108185.	1.7	1
348	Immune Signatures and Systems Biology of Vaccines. , 2011, , 141-167.		2
349	<i>Saccharomyces boulardii</i> improves humoral immune response to DNA vaccines against leptospirosis. <i>Journal of Medical Microbiology</i> , 2017, 66, 184-190.	0.7	9

#	ARTICLE	IF	CITATIONS
350	Protective T cell immunity in mice following protein-TLR7/8 agonist-conjugate immunization requires aggregation, type I IFN, and multiple DC subsets. <i>Journal of Clinical Investigation</i> , 2011, 121, 1782-1796.	3.9	153
351	Clinical Adjuvant Combinations Stimulate Potent B-Cell Responses In Vitro by Activating Dermal Dendritic Cells. <i>PLoS ONE</i> , 2013, 8, e63785.	1.1	13
352	Evaluation of Microflow Digital Imaging Particle Analysis for Sub-Visible Particles Formulated with an Opaque Vaccine Adjuvant. <i>PLoS ONE</i> , 2016, 11, e0150229.	1.1	7
353	Adjuvants and the vaccine response to the DS-Cav1-stabilized fusion glycoprotein of respiratory syncytial virus. <i>PLoS ONE</i> , 2017, 12, e0186854.	1.1	42
354	Immunostimulatory activity of water-extractable polysaccharides from <i>Cistanche deserticola</i> as a plant adjuvant in vitro and in vivo. <i>PLoS ONE</i> , 2018, 13, e0191356.	1.1	29
355	Biopolymer Xanthan: A New Adjuvant for DNA Vaccines. <i>Brazilian Archives of Biology and Technology</i> , 0, 63, .	0.5	3
356	Adjuvant effect of liposome-encapsulated natural phosphodiester CpG-DNA. <i>BMB Reports</i> , 2011, 44, 758-763.	1.1	19
357	Identification of Molecular Signatures from Different Vaccine Adjuvants in Chicken by Integrative Analysis of Microarray Data. <i>Asian-Australasian Journal of Animal Sciences</i> , 2016, 29, 1044-1051.	2.4	1
358	Immune Responses of Mice Immunized with HBsAg Formulated in Naloxone/Alum Mixture: Comparison to Fendrix Vaccine. <i>Hepatitis Monthly</i> , 2017, 17, .	0.1	5
359	An Overview of History, Evolution, and Manufacturing of Various Generations of Vaccines. <i>Journal of Archives in Military Medicine</i> , 2017, In Press, .	0.0	16
360	Laser vaccine adjuvants: Light-augmented immune responses. <i>Vaccine</i> , 2021, 39, 6805-6812.	1.7	4
361	Nanoemulsions: Formulation, characterization, biological fate, and potential role against COVID-19 and other viral outbreaks. <i>Colloids and Interface Science Communications</i> , 2021, 45, 100533.	2.0	24
362	MMV-db: vaccinomics and RNA-based therapeutics database for infectious hemorrhagic fever-causing mammarenaviruses. <i>Database: the Journal of Biological Databases and Curation</i> , 2021, 2021, .	1.4	7
363	The Future of Vaccine Discovery and Development. , 2010, , 375-385.		0
364	Induction of innate immunity by nucleic acids: A potential adjuvant for cancer vaccines?. , 2011, , 232-249.		0
365	Improvements in Adjuvants for New-Generation Vaccines. , 2014, , 117-134.		1
366	Mucosal Immunology and Oral Vaccination. , 2014, , 15-42.		1
367	Expression of the Potentially Immunogenic Truncated Glycoprotein E2 (From Viral Bovine Diarrhoea) Tj ETQq1 1 0.784314 rgβT /Over		

#	ARTICLE	IF	CITATIONS
368	Induction of innate immunity by nucleic acids: A potential adjuvant for cancer vaccines?. , 2015, , 248-265.		0
369	Aluminium Adjuvants â€œ A Nanomaterial used as Adjuvants in Human Vaccines for Decades. Open Biotechnology Journal, 2018, 12, 140-153.	0.6	0
371	AÄ± immÄ±nitesi ve yanÄ±tÄ±nÄ± etkileyen faktörler. Osmangaz Journal of Medicine, 0, , 1-5.	0.1	2
372	Crude polysaccharides from Cistanche deserticola Y.C. Ma as an immunoregulator and an adjuvant for foot-and-mouth disease vaccine. Journal of Functional Foods, 2021, 87, 104800.	1.6	5
373	Vaccine and vaccination as a part of human life: In view of Covidâ€19. Biotechnology Journal, 2021, 17, 2100188.	1.8	9
374	Development and optimisation of hepatitis B recombinant antigen loaded chitosan nanoparticles as an adjuvant using the response surface methodology. Micro and Nano Letters, 2020, 15, 736-741.	0.6	2
375	Role of immunobiotic lactic acid bacteria as vaccine adjuvants. , 2022, , 417-430.		0
376	A Combined Adjuvant TFâ€Al Consisting of TFPR1 and Aluminum Hydroxide Augments Strong Humoral and Cellular Immune Responses in Both C57BL/6 and BALB/c Mice. Vaccines, 2021, 9, 1408.	2.1	0
377	Breast cancer vaccines for treatment and prevention. Breast Cancer Research and Treatment, 2022, 191, 481-489.	1.1	13
378	Aliphatic Polyester Nanoparticles for Drug Delivery Systems. , 0, , .		0
379	Synergistic Action of Immunotherapy and Nanotherapy against Cancer Patients Infected with SARS-CoV-2 and the Use of Artificial Intelligence. Cancers, 2022, 14, 213.	1.7	0
380	Application of Nanoemulsions in the Vaccination Process. Advances in Chemical and Materials Engineering Book Series, 2022, , 494-516.	0.2	0
381	Attacking the Intruder at the Gate: Prospects of Mucosal Anti SARS-CoV-2 Vaccines. Pathogens, 2022, 11, 117.	1.2	9
382	An aluminum hydroxide:CpG adjuvant enhances protection elicited by a SARS-CoV-2 receptor binding domain vaccine in aged mice. Science Translational Medicine, 2022, 14, .	5.8	57
383	Integrating plant molecular farming and materials research for next-generation vaccines. Nature Reviews Materials, 2022, 7, 372-388.	23.3	65
384	An aluminum hydroxide:CpG adjuvant enhances protection elicited by a SARS-CoV-2 receptor-binding domain vaccine in aged mice. Science Translational Medicine, 2021, , eabj5305.	5.8	4
385	Anti-COVID-19 Nanomaterials: Directions to Improve Prevention, Diagnosis, and Treatment. Nanomaterials, 2022, 12, 783.	1.9	10
386	Malaria transmission-blocking conjugate vaccine in ALFQ adjuvant induces durable functional immune responses in rhesus macaques. Npj Vaccines, 2021, 6, 148.	2.9	14

#	ARTICLE	IF	CITATIONS
387	Nano toolbox in immune modulation and nanovaccines. Trends in Biotechnology, 2022, 40, 1195-1212.	4.9	31
388	Precision Vaccine Adjuvants for Older Adults: A Scoping Review. Clinical Infectious Diseases, 2022, 75, S72-S80.	2.9	12
389	Differential Dual-Release Bilayer Microneedles Loaded with Aluminum Adjuvants as a Safe and Effective Vaccine Platform. Advanced Functional Materials, 2022, 32, .	7.8	14
390	An Ultrahigh-Density Microneedle Array for Skin Vaccination: Inducing Epidermal Cell Death by Increasing Microneedle Density Enhances Total IgG and IgG1 Immune Responses. Advanced NanoBiomed Research, 2022, 2, .	1.7	6
391	Improving adjuvanticity of crude polysaccharides from cultivated Artemisia rupestris L. for influenza vaccine by promoting long-term immunity and TH1/TH2 response with dose-sparing effect. Journal of Ethnopharmacology, 2022, 294, 115350.	2.0	1
392	Immunization with a bicistronic DNA vaccine modulates systemic IFN- β and IL-10 expression against Vibrio cholerae infection. Journal of Medical Microbiology, 2022, 71, .	0.7	1
393	Lipid based nanocarriers: Production techniques, concepts, and commercialization aspect. Journal of Drug Delivery Science and Technology, 2022, 74, 103526.	1.4	8
394	Lipid nanoparticles and nanoemulsions exploited in the diagnosis and treatment of infectious diseases. , 2022, , 229-273.		0
395	Nanotechnology-based approaches against COVID-19. , 2022, , 305-364.		0
396	Nanotechnology for the management of COVID-19 during the pandemic and in the post-pandemic era. National Science Review, 2022, 9, .	4.6	11
397	Screening immune adjuvants for an inactivated vaccine against Erysipelothrix rhusiopathiae. Frontiers in Veterinary Science, 0, 9, .	0.9	6
398	Mycobacterium tuberculosis dormancy regulon proteins Rv2627c and Rv2628 as Toll like receptor agonist and as potential adjuvant. International Immunopharmacology, 2022, 112, 109238.	1.7	5
399	Protective and vaccine dose-sparing efficacy of Poly I:C-functionalized calcium phosphate nanoparticle adjuvants in inactivated influenza vaccination. International Immunopharmacology, 2022, 112, 109240.	1.7	1
400	Applications of chitosan derivatives as adjuvant for nanoparticles based vaccines. Infectious Disorders - Drug Targets, 2022, 22, .	0.4	0
402	Induction of protein specific antibody by carbonated hydroxy apatite as a candidate for mucosal vaccine adjuvant. Dental Materials Journal, 2022, 41, 710-723.	0.8	2
403	Adjuvant effect of IRES-based single-stranded RNA on melanoma immunotherapy. BMC Cancer, 2022, 22, .	1.1	0
404	New vector and vaccine platforms: mRNA, DNA, viral vectors. Current Opinion in HIV and AIDS, 2022, 17, 338-344.	1.5	7
405	Noadjuvants Actively targeting lymph node conduits and blocking tumor invasion in lymphatic vessels. Journal of Controlled Release, 2022, 352, 497-506.	4.8	4

#	ARTICLE	IF	CITATIONS
406	Self-Assembly of Immune Signals to Program Innate Immunity through Rational Adjuvant Design. <i>Advanced Science</i> , 2023, 10, .	5.6	11
407	Microbial exopolysaccharides- β -glucans as promising postbiotic candidates in vaccine adjuvants. <i>International Journal of Biological Macromolecules</i> , 2022, 223, 346-361.	3.6	9
408	Nonclinical safety assessments of a novel synthetic toll-like receptor 4 agonist and saponin based adjuvant. <i>Toxicology and Applied Pharmacology</i> , 2022, , 116358.	1.3	0
409	Vaccines and Vaccine Adjuvants for Infectious Diseases and Autoimmune Diseases. <i>Vaccines</i> , 2023, 11, 202.	2.1	1
410	A Biodegradable Antigen Nanocapsule Promotes Anti-Tumor Immunity via the cGAS-STING Pathway. <i>Advanced Functional Materials</i> , 2023, 33, .	7.8	3
411	Current Progress and Challenges in the Study of Adjuvants for Oral Vaccines. <i>BioDrugs</i> , 2023, 37, 143-180.	2.2	9
412	A Biomimetic, Silaffin R5-Based Antigen Delivery Platform. <i>Pharmaceutics</i> , 2023, 15, 121.	2.0	1
413	Polymer-based adjuvant requirements for vaccines. , 2022, , 177-204.		0
414	Molecular DNA dendron vaccines. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2023, 120, .	3.3	4
415	Highlights into historical and current immune interventions for cancer. <i>International Immunopharmacology</i> , 2023, 117, 109882.	1.7	2
416	Pulmonary Application of Novel Antigen-Loaded Chitosan Nano-Particles Co-Administered with the Mucosal Adjuvant C-Di-AMP Resulted in Enhanced Immune Stimulation and Dose Sparing Capacity. <i>Pharmaceutics</i> , 2023, 15, 1238.	2.0	2
417	Silver nanoparticles combat <i>Salmonella Typhimurium</i> : Suppressing intracellular infection and activating dendritic cells. <i>Colloids and Surfaces B: Biointerfaces</i> , 2023, 226, 113307.	2.5	0
418	Emerging trends in vaccine delivery systems. , 2022, , 361-386.		0
419	Expression of FMD virus-like particles in yeast <i>Hansenula polymorpha</i> and immunogenicity of combine with CpG and aluminum adjuvant. <i>Journal of Veterinary Science</i> , 2023, 24, .	0.5	1
420	Tracing the recent updates on vaccination approaches and significant adjuvants being developed against HIV. <i>Expert Review of Anti-Infective Therapy</i> , 2023, 21, 431-446.	2.0	0
421	A Small Molecule RIG-I Agonist Serves as an Adjuvant to Induce Broad Multifaceted Influenza Virus Vaccine Immunity. <i>Journal of Immunology</i> , 2023, 210, 1247-1256.	0.4	2
422	Materials engineering strategies for cancer vaccine adjuvant development. <i>Chemical Society Reviews</i> , 2023, 52, 2886-2910.	18.7	19
423	SARS-CoV-2: Immunity, Challenges with Current Vaccines, and a Novel Perspective on Mucosal Vaccines. <i>Vaccines</i> , 2023, 11, 849.	2.1	12

#	ARTICLE	IF	CITATIONS
429	Worldwide Efforts for the Prevention of Visceral Leishmaniasis Using Vaccinations. , 2023, , 413-426.		0